Resection margins obtained with patient-specific instruments for resecting primary pelvic bone sarcomas: A case-control study.

Robin Evrard¹, Thomas Schubert¹, Laurent Paul², Pierre-Louis Docquier³

¹Neuro Musculo-Skeletal Laboratory (NMSK), secteur des sciences de la santé, institut de recherche expérimentale et clinique, université catholique de Louvain, avenue Mounier 53, 1200 Brussels, Belgium; Service d'orthopédie et de traumatologie de l'appareil locomoteur, cliniques universitaires Saint-Luc, avenue Hippocrate 10, 1200 Brussels, Belgium; Cancérologie et hématologie, institut Roi-Albert-II, cliniques universitaires Saint-Luc, avenue Hippocrate 10, 1200 Brussels, Belgium.

²3D-Side, 5, rue André-Dumont, Mont-Saint-Guibert, Belgium.

³Neuro Musculo-Skeletal Laboratory (NMSK), secteur des sciences de la santé, institut de recherche expérimentale et clinique, université catholique de Louvain, avenue Mounier 53, 1200 Brussels, Belgium; Service d'orthopédie et de traumatologie de l'appareil locomoteur, cliniques universitaires Saint-Luc, avenue Hippocrate 10, 1200 Brussels, Belgium; Cancérologie et hématologie, institut Roi-Albert-II, cliniques universitaires Saint-Luc, avenue Hippocrate 10, 1200 Brussels, Belgium. Electronic address: pierre-louis.docquier@uclouvain.be.

PubMed DOI

Abstract

BACKGROUND: Limb salvage surgery for pelvic bone sarcoma carries a very high risk of local recurrence. Patient-specific instruments (PSIs) have shown promise for obtaining tumour-free resection margins. However, no data are available on medium-term outcomes including local recurrence rates after PSI-guided resection. The objectives of this case-control study were to determine whether PSI-guided re…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.